In Q1 2023, Rock Springs Capital held 88 positions worth $3.6B. They initiated 88 new positions. Their largest holding was HUM ($207.0M).
Frequently asked questions
What stocks did Rock Springs Capital own in Q1 2023?
Rock Springs Capital held 88 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include HUM, AGL, PODD, IMCR, ARGX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Rock Springs Capital's portfolio worth in Q1 2023?
Rock Springs Capital's tracked biotech portfolio was worth $3.6B across 88 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Rock Springs Capital buy in Q1 2023?
Rock Springs Capital initiated 88 new positions in Q1 2023, including HUM, AGL, PODD, IMCR, ARGX and 83 more. They also increased 0 existing positions.
What did Rock Springs Capital sell in Q1 2023?
Rock Springs Capital did not fully exit any positions in Q1 2023.
Is Rock Springs Capital a biotech fund?
Concentrated long/short healthcare fund focused on fundamental research. Rock Springs takes conviction-weighted positions based on deep pipeline analysis, therapeutic area expertise, and a willingness to be contrarian when the science supports it.
Want AI analysis, insider signals, and catalyst overlays for Rock Springs Capital?
View latest Rock Springs Capital portfolio →